What Is Kisspeptin-10?

Published August 2026 · Patriot Labs Research Team · ~16 min read

A decapeptide named after a chocolate

Most compounds in this catalogue were named by a medicinal chemist or a clinical-trials office. Kisspeptin was named by a cancer laboratory that happened to be down the road from a chocolate factory. In 1996 a group at the Penn State College of Medicine in Hershey, Pennsylvania, identified a gene that suppressed the spread of malignant melanoma and called it KiSS-1 — the capitalised letters a deliberate nod to the town's Hershey's Chocolate Kisses.¹ At that point nobody involved was thinking about hormones. KiSS-1 was a tumour-biology gene, and the story might have stayed there.

It did not. In 2001 three laboratories, working independently, showed that the KiSS-1 gene product is cut into a family of secreted peptides that are the natural ligands of an orphan receptor — a G-protein-coupled receptor whose signalling partner had not yet been found.^2,3,4 The peptides were christened kisspeptins, and the longest of them, a 54-residue chain, was given the separate name metastin for its metastasis-suppressing activity. Two years later, in 2003, human and mouse genetics delivered the twist that made kisspeptin famous: switching the receptor off does not cause cancer — it stops puberty.^5,6

Kisspeptin-10 is the working end of that molecule. It is the last ten amino acids of kisspeptin-54, the shortest fragment that still fully activates the receptor, and it is the form most often reached for in laboratory work because it is short, defined, and chemically straightforward to synthesise. Understanding it means understanding the whole family, so this guide starts with the chemistry and builds up to the circuitry.

The chemistry: an amidated decapeptide

Kisspeptin-10 is a linear peptide of ten residues. In one-letter code the human sequence is YNWNSFGLRF; written out, that is H-Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH₂.⁷ It is registered under CAS number 374675-21-5, carries the molecular formula C₆₃H₈₃N₁₇O₁₄, and has an average molecular weight of roughly 1302.4 g/mol.⁷ Depending on the supplier or paper it may appear as Kp-10, metastin (45–54), or KiSS-1 (112–121) — three names for the same ten residues, numbered against different reference frames.

The detail that matters most is at the very end of the chain. The final two residues are arginine and phenylalanine, and the C-terminus is amidated rather than left as a free carboxylic acid. That Arg-Phe-NH₂ ending is the signature of the RFamide peptide family, a group of neuropeptides defined by exactly this motif, and it is not decorative: the amide and the two terminal residues are required for the peptide to bind and activate its receptor. Removing the amide, or truncating the C-terminus, sharply reduces activity in the published structure–activity work. In effect the business end of kisspeptin-10 is its tail, which is why the ten-residue fragment — carrying the full C-terminal motif — behaves like the full-length hormone at the receptor.

The rest of the sequence contributes an aromatic, moderately hydrophobic body (the tryptophan and two phenylalanines) and a single strongly basic residue in the arginine. That combination — aromatic core, basic tail, amidated terminus — is worth keeping in mind when the discussion turns to handling, because it shapes how the peptide dissolves and how it degrades. For the broader chemistry of why short chains like this behave the way they do, the site's overview of what peptides are is the place to start.

Kisspeptin-10, -13, -14 and -54

The KISS1 gene does not encode kisspeptin-10 directly. It encodes a precursor protein of 145 amino acids, which is processed by proteolytic cleavage into a set of shorter peptides that all share the same C-terminal decapeptide. The longest mature product is kisspeptin-54 (metastin); cleavage also yields fragments of 14 and 13 residues, and the ten-residue kisspeptin-10 sits at the C-terminal tip of all of them. Because they converge on the identical Arg-Phe-amide ending, all four are agonists at the same receptor with, in isolated systems, broadly similar potency.

Where they differ is in the body, not the test tube. The longer chains carry additional structure that slows their breakdown, whereas kisspeptin-10 is small and is cleared from plasma very quickly — on the order of minutes — once it is exposed to peptidases. That single pharmacokinetic contrast explains much of how the fragments have been used in research: the shorter kisspeptin-10 for acute, defined-window experiments, and the longer kisspeptin-54 where a more sustained exposure was wanted.

One practical consequence: results reported for one fragment do not transfer automatically to another, and careful papers specify exactly which kisspeptin they used. A study of kisspeptin-54 in a clinical setting and a bench experiment with kisspeptin-10 are studying the same signalling motif through molecules with different lifetimes.

One receptor, three names

Kisspeptins act on a single receptor that, like the peptide itself, collected several names before its identity settled. It is now called KISS1R. It was first described as the orphan receptor GPR54, and independently as AXOR12 and hOT7T175 by other groups working on the same sequence. All of these refer to one G-protein-coupled receptor.

KISS1R signals principally through the Gq/11 pathway. Agonist binding activates phospholipase C, which generates the second messengers inositol trisphosphate and diacylglycerol and mobilises calcium from intracellular stores. In the cells where it matters most for reproduction — gonadotropin-releasing hormone neurons — this calcium signalling depolarises the neuron and drives it to fire, which is the physical link between a kisspeptin pulse and a downstream hormone pulse. The receptor also undergoes the desensitisation and internalisation typical of GPCRs on sustained stimulation, a property that becomes relevant to any discussion of continuous versus pulsatile exposure.

The "deorphanising" of GPR54 in 2001 — matching an orphan receptor to its natural ligand — is the hinge of the whole story. Before it, KiSS-1 was a tumour-suppressor gene and GPR54 was a receptor looking for a job. After it, the two were a matched pair, and the search for what that pair actually did in the body was on.

From metastasis suppressor to master switch

The 2003 finding is worth telling in full, because it is one of the cleaner examples of human genetics rewriting a molecule's job description. Two groups — one led from Paris by de Roux and colleagues, publishing in PNAS, and one centred on Massachusetts General Hospital and Cambridge led by Seminara and colleagues, publishing in the New England Journal of Medicine — were studying families with idiopathic hypogonadotropic hypogonadism: patients who fail to enter puberty because the reproductive hormone axis never switches on, with no anatomical cause.^5,6

Both groups traced the condition to loss-of-function mutations in the same gene: GPR54 / KISS1R. The interpretation was immediate and striking. If breaking the kisspeptin receptor prevents puberty, then kisspeptin signalling is not a minor modulator of reproduction — it is a required switch, positioned high in the control hierarchy. Mouse models with the receptor deleted reproduced the phenotype, and the field reorganised around a new picture in which kisspeptin neurons sit at the top of the axis. A decade of subsequent work, reviewed repeatedly since, has treated kisspeptin as a principal gatekeeper of the onset of puberty and of adult fertility.^8,9

It is a genuinely unusual arc: a gene found in a cancer screen, named for a local chocolate, matched to an orphan receptor, and then revealed by rare human mutations to be a master regulator of a completely different system. The cancer-biology thread did not disappear — KISS1 expression is still studied in tumour metastasis — but the reproductive role is what made kisspeptin a household name inside endocrinology.

How kisspeptin sits above GnRH

The reproductive axis is usually drawn as a three-tier cascade: the hypothalamus releases gonadotropin-releasing hormone (GnRH) in pulses, the pituitary responds with luteinising hormone and follicle-stimulating hormone, and the gonads respond to those. The question the 2003 genetics forced was: what tells the GnRH neurons when to fire? A large part of the answer is kisspeptin. For readers who want the wider circuit, the site's guide to the HPG-axis peptides maps how these signals connect.

Kisspeptin neurons are found in two main hypothalamic locations. One population sits in the arcuate nucleus, where the same neurons co-express two other neuropeptides — neurokinin B and dynorphin — which is why they are known by the acronym KNDy (Kisspeptin, Neurokinin B, Dynorphin). A second population sits in the rostral periventricular area (the AVPV in rodents). The KNDy neurons are the ones most closely tied to the rhythmic behaviour of the axis.

The current model of GnRH pulse generation is a small, self-organising network. In a recent review of the field, the arcuate KNDy neurons are described as "a central node in the regulation of GnRH/LH release and a key component of the pulse generator," with the reciprocally connected population synchronising to produce each pulse.⁸ Within that network the three peptides have different jobs: neurokinin B acts on the KNDy cells to synchronise their firing and start a pulse, dynorphin provides the inhibitory brake that ends it, and kisspeptin is the output — the signal these neurons send onward to the GnRH neurons to make them fire. As the review puts it, "kisspeptin release from KNDy cells serves as the output driving GnRH and gonadotrophin release."⁸

This is what "sitting above GnRH" means concretely. Kisspeptin is not another word for GnRH and it is not downstream of it; it is the upstream signal that switches GnRH neurons on, and it is one of the most potent stimulators of GnRH release identified. The same kisspeptin neurons also carry receptors for metabolic and steroidal signals — they are a documented site where energy-balance information such as leptin status and the feedback of sex steroids converge on the reproductive axis — which is why kisspeptin is often described as the integrator that links whether the body has the resources for reproduction with whether the axis runs.⁹

The human research record

Kisspeptin is unusual among research peptides in having a substantial human investigational literature, generated in academic settings under regulated protocols. The most developed line of that work used the longer kisspeptin-54 fragment as a tool in reproductive medicine research.

The central example comes from the group of Professor Waljit Dhillo at Imperial College London. In work reported in 2014 in the Journal of Clinical Investigation, kisspeptin-54 was studied as an alternative trigger for the final maturation of eggs in women undergoing in-vitro fertilisation.¹⁰ The rationale was mechanistic: the standard trigger, human chorionic gonadotropin, is long-acting and can over-stimulate the ovaries, contributing to ovarian hyperstimulation syndrome (OHSS) — a complication the researchers described as potentially serious. Because kisspeptin acts upstream and is cleared quickly, the hypothesis was that it could induce egg maturation through the body's own hormone surge while breaking down fast enough to reduce the overstimulation risk. A follow-up study published in the Journal of Clinical Endocrinology & Metabolism in 2015 extended the approach to women already at high risk of OHSS.¹¹

Two points about this record matter for a research audience. First, it is real, peer-reviewed human science, not marketing extrapolation. Second, it studied kisspeptin-54 in a tightly controlled clinical-trial environment; it is a demonstration of the signalling motif's biology, not a template that transfers to research-grade kisspeptin-10 in any other setting. The value of the work here is that it establishes, in humans, that activating this receptor drives the reproductive hormone cascade as the animal models predicted.

The investigational thread has continued into the present. Human studies published across 2025 and 2026 have kept probing what kisspeptin administration does and does not do — for example a 2025 JCEM report examining whether kisspeptin affects anxiety alongside its reproductive-hormone effects, and continuing review coverage of how kisspeptin and neurokinin B biology might translate into reproductive-health research tools.^12,13 The picture that emerges is of a signalling system still being characterised rather than a settled therapeutic.

Beyond reproduction

The reason kisspeptin keeps appearing in recent literature is that its studied role has widened beyond the hypothalamus. Because kisspeptin neurons and their receptor are also found in limbic and paralimbic brain regions — areas associated with emotion and motivation — researchers have asked whether the signal does more than gate hormone release.

The most cited work here again comes from the Imperial College group. A 2017 study in the Journal of Clinical Investigation, "Kisspeptin modulates sexual and emotional brain processing in humans," used functional MRI to examine brain activity during administration, and reported changes in the activity of networks involved in sexual and emotional processing.¹⁴ Subsequent imaging work extended the observations to resting-state brain connectivity and to responses to olfactory and visual cues.¹⁵ Kisspeptin's receptors have also been documented outside the brain — in the placenta, where the parent molecule is highly expressed, and in a range of peripheral tissues — and its cancer-biology origins keep a separate literature alive in tumour metastasis.

The through-line of the 2020s literature, including the multi-domain reviews appearing in 2026, is that kisspeptin is being examined as a multifunctional signal spanning reproduction, brain processing, metabolism and beyond, rather than a single-purpose reproductive hormone. For a research programme, that breadth is precisely what makes a well-characterised decapeptide like kisspeptin-10 a useful reference agonist: it engages a receptor system whose full biology is still being mapped.

Bench practice: handling an amidated decapeptide

Kisspeptin-10 is supplied as a lyophilised (freeze-dried) solid, and its handling profile follows from the chemistry described above. It is a small, amidated peptide with a basic arginine and an aromatic core; it is generally water-soluble, and the amidated terminus is part of what the receptor recognises, so preserving molecular integrity is the whole point of careful handling. The general principles are the same as for any research peptide and are covered in the site's storage guide and its discussion of how peptides degrade; the notes below are what is specific to this molecule.

Because the intact sequence — and particularly the C-terminal motif — is what carries the biology, the analytical questions a laboratory should be able to answer about a vial are identity and purity. Identity is established by mass spectrometry: the observed mass should match the expected value for the amidated decapeptide (an average near 1302.4). Purity is established by reversed-phase HPLC, which resolves the target peak from synthesis-related impurities and any degradation products. A credible certificate of analysis reports both, along with net peptide content and, for many workflows, counter-ion and endotoxin information. The site's guide to reading a peptide COA explains what those numbers mean and where they can mislead.

Two chemistry-specific cautions. First, RFamide peptides can be susceptible to loss of the C-terminal amide or to clipping of terminal residues under harsh conditions, and either change would alter the very part of the molecule the receptor reads — another reason a defined identity check matters. Second, oxidation-prone residues and the general fragility of a short chain in solution mean that reconstituted material does not have the indefinite stability of the dry solid. None of this is a use instruction; it is the analytical hygiene that lets a laboratory trust that what is in the vial is the sequence on the label.

What the evidence does not establish

The kisspeptin literature is unusually strong on mechanism and genetics, and it is important not to over-read it. The human work that exists was performed in controlled academic research, much of it with kisspeptin-54 rather than kisspeptin-10, and it characterises a signalling system — it does not convert a research peptide into an approved product or a self-administration protocol. There is no approved kisspeptin-10 drug for general use.

The genetics that made kisspeptin famous cut both ways as evidence. They show that the receptor is necessary for normal puberty, which is a strong statement about biology. They do not show that adding more agonist produces a proportionate or safe effect in any setting, and the receptor's tendency to desensitise under continuous stimulation is a reminder that "more signal" and "more output" are not the same thing in a pulsatile system. The imaging findings on emotional and sexual brain processing are real and peer-reviewed, but they are early, small, and mechanistic rather than a demonstration of any applied outcome.

The honest summary is that kisspeptin-10 is one of the best-defined agonists available for a receptor system of genuine scientific importance, whose full physiology — especially outside reproduction — is still being worked out. That is exactly why it belongs in a research setting and nowhere else.

Frequently asked questions

What does the "kiss" in kisspeptin stand for?

It comes from KiSS-1, the gene name assigned when the sequence was discovered in 1996 as a melanoma metastasis-suppressor gene. The work was done at the Penn State College of Medicine in Hershey, Pennsylvania, and the laboratory chose the letters as a nod to the town's Hershey's Chocolate Kisses. The name predates any knowledge of the peptide's role in reproduction; kisspeptin was a cancer gene before it was a reproductive one.

What is the difference between kisspeptin-10 and kisspeptin-54?

Both are products of the same KISS1 gene. Kisspeptin-54, historically called metastin, is the longer 54-residue peptide. Kisspeptin-10 is the C-terminal decapeptide contained within it. Shorter fragments of 13 and 14 residues also exist. All of them terminate in the same Arg-Phe-amide motif and act on the same receptor with broadly comparable in-vitro potency, but they differ in length and in how quickly they are broken down in plasma.

What receptor does kisspeptin-10 act on?

KISS1R, a G-protein-coupled receptor that was originally described as the orphan receptor GPR54 (and independently as AXOR12 and hOT7T175) before its ligand was known. It couples mainly through the Gq/11 pathway, activating phospholipase C and mobilising intracellular calcium. The receptor was "deorphanised" in 2001 when three groups independently showed that KiSS-1-derived peptides are its natural ligands.

Why is kisspeptin described as sitting "above" GnRH?

Because in the studied circuitry kisspeptin neurons act on gonadotropin-releasing hormone (GnRH) neurons rather than the other way around. Kisspeptin is one of the most potent known stimulators of GnRH release, and a population of kisspeptin neurons in the arcuate nucleus that also express neurokinin B and dynorphin (the KNDy neurons) is regarded as a central component of the GnRH pulse generator. Loss-of-function mutations in the receptor block puberty, which places kisspeptin signalling upstream of GnRH in the hierarchy.

Is kisspeptin-10 approved for human use?

No. Kisspeptin has been administered in academic clinical research under regulated protocols, but there is no approved kisspeptin-10 drug product for general use, and research-grade material is a different thing entirely. Kisspeptin-10 supplied by Patriot Labs is sold strictly for in-vitro research and laboratory use only, is not for human or veterinary consumption, and nothing in this guide describes how to use it. For the practical side of sourcing verified material, see the guide on storing research peptides and the COA explainer.

References

All Patriot Labs products are sold strictly for in-vitro research and laboratory use only. Not for human or veterinary consumption. This guide is educational and describes peptide chemistry and published research in general terms; it is not medical advice, does not describe how to use any product, and the references cited do not constitute a product claim.